3-异丁氧基丙胺 | 32923-88-9

• 物质功能分类: 有机原料 - 氨基化合物 - 无环单胺、多胺及其衍生物和盐
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-异丁氧基丙胺
• 英文名称: 3-isobutoxy-1-propylamine
• 英文别名: 3-isobutoxypropylamine；3-isobutoxypropyl amine；3-isobutoxy-propylamine；1-Amino-3-isobutoxy-propan；3-Isobutoxy-propylamin；3-(2-methylpropoxy)propan-1-amine
• CAS: 32923-88-9
• 化学式: C₇H₁₇NO
• mdl: MFCD00025618
• 分子量: 131.218
• InChiKey: REJGIEGOYWEWPR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2922199090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Isobutoxy propylamine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Isobutoxy propylamine
CAS number: 32923-88-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H17NO
Molecular weight: 131.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-异丁氧基丙胺 、 (2RS,3R) 3-(tert-butoxycarbonylamino)-2-hydroxy-4-cyclohexyl-butanoic acid 生成 (2RS,3R)-3-amino-4-cyclohexyl-2-hydroxy-N-(3-isobutoxypropyl)butanamide Hydrochloride
  参考文献：
  名称：

  Substituted &bgr;-amino acid inhibitors of methionine aminopeptidase-2

  摘要：

  一类取代的β-氨基酸是对蛋氨酸氨基肽酶2（MetAP2）的强效抑制剂，因此在抑制依赖血管生成发展的疾病状况（如糖尿病视网膜病变、肿瘤生长和炎症状况）方面非常有用。还披露了包含这些化合物的药物化合物以及抑制蛋氨酸氨基肽酶-2和血管生成的方法。

  公开号：

  US06242494B1
• 作为产物：
  描述：

  异丁醇 、 3-羟基丙腈 在 sodium 作用下， 生成 3-异丁氧基丙胺
  参考文献：
  名称：

  Kost; Jaschunskii, Zhurnal Obshchei Khimii, 1953, vol. 23, p. 230,237; engl. Ausg. S. 239, 245

  摘要：

  DOI：

文献信息

• Sulfonamides having antiangiogenic and anticancer activity
  申请人：——

  公开号：US20040157836A1

  公开（公告）日：2004-08-12

  Compounds having methionine aminopeptidase-2 inhibitory (MetAP2) are described. Also described are pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, methods of inhibiting angiogenesis, and methods of treating cancer.

  描述了具有蛋氨酸氨基肽酶-2抑制剂（MetAP2）的化合物。还描述了包括这些化合物的药物组合物、使用这些化合物的治疗方法、抑制血管生成的方法以及治疗癌症的方法。
• Disrupting the Conserved Salt Bridge in the Trimerization of Influenza A Nucleoprotein
  作者：Jennifer L. Woodring、Shao-Hung Lu、Larissa Krasnova、Shih-Chi Wang、Jhih-Bin Chen、Chiu-Chun Chou、Yi-Chou Huang、Ting-Jen Rachel Cheng、Ying-Ta Wu、Yu-Hou Chen、Jim-Min Fang、Ming-Daw Tsai、Chi-Huey Wong

  DOI：10.1021/acs.jmedchem.9b01244

  日期：2020.1.9

  threat to public health. To develop a broad-spectrum inhibitor of influenza to combat the problem of drug resistance, we previously identified the highly conserved E339...R416 salt bridge of the nucleoprotein trimer as a target and compound 1 as an inhibitor disrupting the salt bridge with an EC50 = 2.7 μM against influenza A (A/WSN/1933). We have further modified this compound via a structure-based

  流感感染中的抗病毒药物耐药性已成为对公共卫生的主要威胁。为了开发广谱的流感抑制剂来解决耐药性问题，我们之前确定了高度保守的核蛋白三聚体E339 ... R416盐桥为靶标，化合物1为通过EC50破坏盐桥的抑制剂甲型流感病毒= 2.7μM（A / WSN / 1933）。我们通过基于结构的方法进一步修饰了该化合物，并进行了抗病毒活性筛选，以鉴定化合物29和30的EC50值分别为110和120 nM，并且没有可测量的宿主细胞毒性。与临床使用的神经氨酸酶抑制剂相比，这两种化合物对耐药性A型流感病毒株和B型流感病毒显示出更好的活性，
• Substituted dialkanolamines, sulfur analogs and condensed 1,4-oxazine
  申请人：A. H. Robins Company, Incorporated

  公开号：US04803200A1

  公开（公告）日：1989-02-07

  Substituted dialkanolamines, oxazine and sulfur analogs thereof, useful in treating shipping fever syndrome in mammals are disclosed having the formula: ##STR1## wherein: Ar is ##STR2## Z is oxygen or sulfur; R is selected from hydrogen, loweralkyl or ##STR3## R.sup.1 R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are selected from hydrogen or loweralkyl; and ##STR4## when taken together may form a lowercycloalkyl ring or R.sup.5 with --ZR.sup.2 when taken together may form a 5-membered saturated oxygen or sulfur containing heterocyclic ring; X is selected from hydrogen, halo, loweralkoxy, loweralkyl, trifluoromethyl or dimethylamino and when X is more than 1, it may be the same radical or different; y is 0, 1 or 2; n is one, or zero and when n is 1, the stereoisomers thereof and when n is zero the dotted line becomes an oxygen-carbon bond forming an oxazine ring and the pharmaceutically acceptable acid addition salts thereof.

  揭示了在治疗哺乳动物的运输热症候群中有用的取代二烷醇胺、噁唑和其硫代物，其化学式为：##STR1##其中：Ar为##STR2##Z为氧或硫；R从氢、低烷基或##STR3##中选择；R.sup.1、R.sup.2、R.sup.3、R.sup.4、R.sup.5、R.sup.6和R.sup.7中选择自氢或低烷基；和##STR4##当一起取时，可能形成低环烷基环，或者R.sup.5与--ZR.sup.2一起取时，可能形成含氧或硫的5-成员饱和杂环环；X从氢、卤素、低烷氧基、低烷基、三氟甲基或二甲氨基中选择，当X大于1时，可能是相同的基团或不同的基团；y为0、1或2；n为1或零，当n为1时，其立体异构体，当n为零时，虚线变成氧-碳键形成噁唑环及其药用盐。
• [EN] NEW PHOSPHORUS CONTAINING HETEROCYCLIC COMPOUNDS, SUGAR ANALOGUES, AND COMPOSITIONS HAVING ANTI-CANCER ACTIVITY CONTAINING THE SAME<br/>[FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES CONTENANT DU PHOSPHORE, ANALOGUES DE SUCRES, ET COMPOSITIONS AYANT UNE ACTIVITÉ ANTICANCÉREUSE LES CONTENANT
  申请人：CENTRE NAT RECH SCIENT

  公开号：WO2009004096A1

  公开（公告）日：2009-01-08

  The invention provides new anticancer compounds of formula (1) such as defined in the present description. The invention also provides pharmaceutical compositions to be used in human or veterinary medicine, comprising at least one compound of formula (1). The present invention further relates to a compound of formula (1) such as defined in the present description, for use as a drug. The invention further relates to the use of a compound of formula (1) for manufacturing a human or animal anticancer pharmaceutical composition.

  该发明提供了新的抗癌化合物，其化学式为（1），如本说明中所定义。该发明还提供了用于人类或兽医药物的制剂，包括至少一种化合物（1）。本发明进一步涉及一种化合物，其化学式为（1），如本说明中所定义，用作药物。该发明还涉及使用化合物（1）制造人类或动物抗癌药物组合物。
• [EN] CYCLIC PEPTIDE ANTIBIOTICS<br/>[FR] ANTIBIOTIQUES PEPTIDIQUES CYCLIQUES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2019052545A1

  公开（公告）日：2019-03-21

  Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of lipoprotein signal peptidase II (LspA), a key protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

  本文提供了抗菌化合物，其中在某些实施例中，这些化合物具有广谱生物活性。在各种实施例中，这些化合物通过抑制脂蛋白信号肽酶II（LspA）来发挥作用，这是细菌中的关键蛋白质。还提供了使用所述化合物的药物组合物和治疗方法。